STOCK TITAN

Certara, Inc. - CERT STOCK NEWS

Welcome to our dedicated page for Certara news (Ticker: CERT), a resource for investors and traders seeking the latest updates and insights on Certara stock.

Certara, Inc. (NASDAQ: CERT) delivers biosimulation solutions and model-informed drug development services that accelerate pharmaceutical innovation. This page provides comprehensive coverage of Certara's latest news, including regulatory milestones, strategic partnerships, and advancements in simulation technology.

Investors and industry professionals will find timely updates on earnings reports, product launches, and scientific developments shaping the drug development landscape. Our curated collection features press releases on regulatory submissions, technology platform enhancements, and collaborations with biopharma leaders.

Key focus areas include Certara's biosimulation software updates, regulatory science achievements, and innovations in quantitative pharmacology. Bookmark this page to stay informed about developments impacting clinical trial optimization and global drug approval processes.

Rhea-AI Summary

Certara (Nasdaq: CERT), a global leader in model-informed drug development, will announce its Q2 2024 financial results after market close on August 6th, 2024. The announcement will be followed by a conference call at 5:00 PM ET to discuss the results. Investors are advised to register online for the call at least a day in advance. The event will be broadcast live and archived on Certara's investor relations website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.32%
Tags
conferences earnings
-
Rhea-AI Summary

Certara (Nasdaq: CERT) has launched its next-generation CoAuthor regulatory writing software, enhancing the medical writing process using generative AI. Unveiled on June 17, 2024, CoAuthor integrates AI, document templates, and Microsoft Word, aiming to expedite the creation of regulatory documents while maintaining a 'human in the loop' approach. The software allows medical writers to efficiently synthesize complex biomedical data, providing a secure and specialized GPT for the drug development sector.

The platform promises to improve drafting times by at least 30%, enhancing content curation and quality control. Certara’s CEO, William Feehery, emphasized the company's expertise in maximizing AI’s potential in drug development. CoAuthor will be presented at the DIA Annual Meeting in San Diego, featuring a dedicated session on June 17th.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.49%
Tags
AI
-
Rhea-AI Summary

Certara (Nasdaq: CERT), a global leader in biosimulation, announced its participation in the Jefferies Global Healthcare Conference.

The event will take place on June 5th, 2024, at 11:30AM ET.

Company management will present at the conference, and a live webcast will be available on Certara’s investor relations website.

The webcast replay will be accessible for at least 90 days.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.49%
Tags
conferences
Rhea-AI Summary

On May 21, 2024, Certara (Nasdaq: CERT), a global leader in model-informed drug development, announced the appointment of Rona Anhalt as Chief Human Resources Officer and Daniel Corcoran as General Counsel.

CEO William F. Feehery expressed confidence in their ability to enhance Certara's mission to accelerate medicine development. Anhalt, previously with EQRx, will lead human capital management for Certara's 1,400 employees, including 400 scientists. Corcoran, coming from Nexthink, will oversee legal affairs, bringing over 20 years of experience from technology companies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.86%
Tags
management
-
Rhea-AI Summary

Certara, Inc. reported its first quarter 2024 financial results, with revenue reaching $96.7 million, a 7% increase from the previous year. Software revenue grew by 19% to $39.3 million, while services revenue remained flat. The net loss was $4.7 million, with adjusted EBITDA at $29.1 million. The company reiterated its full-year 2024 financial guidance, expecting revenue between $385 million to $400 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.42%
Tags
-
Rhea-AI Summary
Certara, Inc. launches Certara Cloud, a platform integrating its scientific software solutions for model-informed drug development. The platform aims to enhance customer experience, streamline workflows, and provide real-time collaboration and security benefits.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.12%
Tags
none
Rhea-AI Summary
Certara, Inc. (CERT) will release Q1 2024 financial results on May 7th, 2024, followed by a conference call at 5:00PM ET. The company will also participate in the BofA Securities Healthcare Conference on May 14th. Live and archived webcasts will be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.27%
Tags
conferences earnings
-
Rhea-AI Summary
Certara, Inc. provides full-year 2024 financial guidance, reporting $88.0 million in revenue for the fourth quarter of fiscal year 2023, a 2% increase over the previous year. The net loss was $12.5 million due to increased operating expenses and fair value adjustments. The company aims to grow in 2024 with investments in new software products and artificial intelligence capabilities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.41%
Tags
-
Rhea-AI Summary
Certara, Inc. (CERT) will release its financial results for Q4 and full year 2023 on February 29th, 2024. The company will also participate in the Barclays 26th Annual Global Healthcare Conference on March 13th. Live and archived webcasts will be available on the Certara website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.12%
Tags
conferences earnings
Rhea-AI Summary
Certara, Inc. (Nasdaq: CERT) has acquired Applied BioMath, establishing the life sciences industry’s largest quantitative systems pharmacology (QSP) center of excellence. This acquisition aims to contribute to faster and more effective medicine development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.73%
Tags
Certara, Inc.

Nasdaq:CERT

CERT Rankings

CERT Stock Data

2.28B
121.01M
2.27%
96.57%
3.34%
Health Information Services
Services-prepackaged Software
Link
United States
RADNOR